Ault-onomous Episode #2: Stephan Jackman

For the second episode of my podcast series, I sat down Alzamend Neuro CEO Stephan Jackman to discuss the exciting developments in his field of biotechnology. The information provided is for informational purposes, only. The information herein should not be taken as financial, investment or legal advice and should not be construed as an offer to buy or sell or an offer to buy or sell any security or instrument or to participate in any transaction or trading activity. Neither program nor its guests make any guarantee or other promise as to any results that may be obtained from using our content. No one should make any investment decision without first consulting his or her own financial advisor and conducting his or her own research and due diligence. This program does not make any recommendations regarding the appropriateness of particular investment opportunities for any investor. My team and I focus on undervalued assets, disruptive technologies with a global impact. Our companies span various market segments including: Advanced digital manufacturing technology, defense and aerospace, bio technologies, hospitality, corporate lending, as well as real estate investment. Our offering will be made pursuant to Rule 506(c) of the Securities Act of 1933, and only to accredited investors. There is no assurance that we will raise $100 million. The information presented in the video does not constitute an offer to sell or a solicitation of an offer to purchase any security in the United States or elsewhere and shall not constitute an offer or sale where, or to any person to whom, such an offer or sale would be unlawful.